Hjem › Atopisk dermatitt (eksem) › Indiana
Kliniske studier for Atopisk dermatitt (eksem) i Indiana
9 studier for Atopisk dermatitt (eksem) søker deltakere på steder i Indiana.
Byer i Indiana
Offisiell studietekst (engelsk)
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
- Clinical Site 106, Plainfield
RekruttererFase 1Frivillige helsepersonell ønskes velkommen
Alder 18 til 65 · Alle kjønn · Oppdatert 29. sep. 2026 · NCT07453602Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Clarksville
- Enveda Investigative Site, New Albany
- Enveda Investigative Site, West Lafayette
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07298395A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
- Dawes Fretzin Clinical Research Group, LLC, Indianapolis
RekruttererFase 3
Alder 2 til 11 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06807281A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
- DS Research of Southern Indiana,LLC, Clarksville
- Dawes Fretzin Clinical Research Group, LLC, Indianapolis
RekruttererFase 2
Alder 18 til 65 · Alle kjønn · Oppdatert 28. aug. 2026 · NCT07599813A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Indianapolis
- Enveda Investigative Site, Plainfield
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 6. aug. 2026 · NCT07643766A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
- Dawes Fretzin /ID# 265097, Indianapolis
RekruttererFase 3
Alder 2 til 11 · Alle kjønn · Oppdatert 6. aug. 2026 · NCT06461897A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- Options Research Group /ID# 264564, West Lafayette
RekruttererFase 3
Alder 18 til 63 · Alle kjønn · Oppdatert 6. jul. 2026 · NCT06389136A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
- Dawes Fretzin Clinical Research Group, LLC, Indianapolis
- Southern Indiana Clinical Trials, New Albany
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 4. mai 2026 · NCT05995964Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
- Galderma Investigational Site 8142, Indianapolis
- Galderma Investigational Site 7083, West Lafayette
RekruttererObservasjonsstudie
Alder 12 og eldre · Alle kjønn · Oppdatert 13. mar. 2026 · NCT06988605Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.